epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

Nat Med

Weight training cut lean mass loss on tirzepatide by almost a quarter

November 15, 2026

card-image

Clinical takeaway: Consider referring sedentary adults starting tirzepatide to supervised resistance training three times a week. It slowed lean mass loss but did not stop it. 

Patients on tirzepatide and similar obesity drugs lose lean tissue as well as fat. Studies of incretin therapy have put the loss at 11% to 14% of lean soft tissue. That’s a concern for middle-aged and older patients on these drugs, since muscle loss predisposes them to health issues including sarcopenia and frailty. 

Two muscle-preserving drugs are in testing, but both are given by infusion and are years from reaching patients. Resistance training is available, yet it had not been assessed alongside a potent incretin mimetic from the start of treatment. A randomized trial now tests whether the pairing protects lean tissue and strength. 

Patients who trained lost 3.57 kg (7.9 lbs) of lean soft tissue, against 4.67 kg (10.3 lbs) on tirzepatide alone, a 1.09 kg (2.4 lbs) difference with a plausible range of 0.43 to 1.75 kg (0.9 to 3.9 lbs). Training slowed the loss without stopping it, and the arms and legs followed the same pattern, losing 2.92 kg (6.4 lbs) against 3.55 kg (7.8 lbs). Total lean loss leveled off after week 24 in both groups. 

Weight and fat loss did not differ. Both groups lost about 22 kg (about 49 lbs) of body weight and 17 to 18 kg (37 to 40 lbs) of fat, so training changed what came off but not how much. 

But patients on tirzepatide alone lost about 6% to 9% of their strength on bench press, lat pulldown, and knee extension, while trained patients actually gained about 11% to 18%. The widest difference was on lat pulldown, where trained patients finished 12.97 kg (28.6 lbs) ahead. 

Training added nothing to cardiometabolic results. Blood pressure, glucose, A1C, total cholesterol, and triglycerides improved to a similar degree in both groups, with systolic pressure falling 15.3 mmHg on tirzepatide alone and 16.6 mmHg with training. 

The T-REx trial randomized 120 sedentary adults aged 50 to 70, half men and half postmenopausal women, who had obesity or overweight with a related condition and no diabetes or cardiovascular disease. All started tirzepatide and titrated toward 15 mg weekly, at a single center in Perth, Australia. Sixty-one kept to usual activities while 59 added three supervised group resistance sessions a week for 40 weeks, attending 91% of sessions on average. Scans using dual-energy X-ray absorptiometry measured lean tissue every eight weeks. 

Training ran in a dedicated gym under accredited exercise physiologists, so the next test is whether routine practice can match it. Whether the lean tissue difference translates to fewer falls, fractures, or cardiovascular events is also untested, since patients were followed for tissue and strength, not those outcomes. Reports on fitness, vascular function, and heart function from the same patients are still to come. 

“With GLP-1 medicines now widely used and reducing body weight by an average of 20-25 percent, and more than that in many people, it’s crucial that we understand how best to achieve optimal body composition and health in the weight-reduced state,” said Daniel Green, PhD, lead investigator and a professor of exercise and sport science at the University of Western Australia. “We now know that muscle loss can be reduced and strength increased when regular resistance training is used alongside tirzepatide treatment.” 

Source: Green DJ, et al. (2026 Nov 9) Nat Med. Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial

learn more about epocrates plus

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & FeedbackCookie Preferences
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information